Wat is Retatrutide?
Rtel(R & D-kodeLY3437943) is 'n inspuitbare polipeptiedmiddel wat ontwikkel is deur Eli Lilly, wat 'n nuwe generasie inkretien (inkretien) gewigsverlies en hipoglisemiese kandidaatmiddel is. Die mees opvallende kenmerk daarvan is die "drievoudige agonis" (drievoudige agonis) ontwerp: 'n enkele molekule kan gelyktydig drie verskillende metaboliese reseptore aktiveer: glukagon-agtige peptied -1 reseptor (GLP-1), glukose-afhanklike insulinotropiese polipeptied reseptor (GIP) en glukagon reseptor.
Struktureel is Retatrutide 'n vetsuur-gemodifiseerde sintetiese polipeptied waarvan die ruggraat gebaseer is op die glukagon/GLP-1-familievolgorde en wat via 'n sykettingvetsuur aan albumien bind vir verlengde halfleeftyd. Hierdie wysiging maak dit moontlik om 'n doseringsfrekwensie van een keer weeklikse onderhuidse inspuiting te bereik, wat ooreenstem met die GLP-1-middelafleweringsmetodes wat tans op die mark is en langtermyngebruik vergemaklik.
Die agtergrond vir die ontwikkeling van die Retatrutide spruit uit die vinnige evolusie van die veld van vetsugbehandeling. Eerstegenerasie-middels soos semaglutied is enkel-GLP-1-agoniste wat ongeveer 15-17% gewigsverlies kan behaal; tweede generasie telpotied (tirzepatied) is 'n dubbele GLP-1/GIP agonis wat gewigsverlies tot ongeveer 20-22% kan verhoog. Die Retatrutide verteenwoordig 'n verdere uitbreiding van die "multi-reseptor sinergie" strategie, wat poog om deur die plafon van gewigsverlies te breek deur 'n derde teiken te oorlê.
Dit is die moeite werd om te beklemtoon dat Retatrutide nog in die kliniese navorsingstadium is,dit is nie deur enige regulerende liggaam vir menslike behandeling goedgekeur nie.. Hierdie artikel is slegs vir opvoedkundige doeleindes en is nie mediese advies nie. Enige besluite wat verband hou met gewigsbestuur of metaboliese siektes moet onder die leiding van 'n gekwalifiseerde mediese beroep geneem word. Buiten kliniese proewe word Retatrutide ook in Europa verkoop in die vorm van voorafgevulde penne vir navorsingsgebruik.
Hoe werk drievoudige agoniste?
Om die meganisme van Retatrutide te verstaan, moet ons die fisiologiese rol van elk van die drie reseptore wat dit teiken, verstaan. Hierdie drie weë speel komplementêre rolle in energiebalans en bloedsuikerregulering, en die kerninnovasie van die Retatrutide is om hulle in dieselfde molekule te integreer om 'n sinergistiese effek te skep.
GLP-1 reseptor agonismedie basiese meganisme. Aktivering van GLP-1-reseptore kan glukose-afhanklike insulienafskeiding verbeter, die onvanpaste vrystelling van glukagon inhibeer, maaglediging vertraag en op die hipotalamus-eetlussentrum inwerk om versadiging te verbeter en voedselinname te verminder. Dit is die hoofbron van die gewigsverlies-effek van selmegraglutied en tilpotied.
GIP reseptor agonismebied 'n tweede laag van aksie. GIP is ook 'n inkretien wat postprandiale insulienafskeiding sinergisties verhoog en word vermoedelik vetweefsel metaboliese funksie en insulien sensitiwiteit verbeter. Die gekombineerde effek van GIP en GLP-1 is een van die belangrikste redes waarom telpotied beter is as enkel GLP-1 middels.
glukagon reseptor agonismedit is die beslissende derde teiken wat Retatrutide van tilpotide onderskei. Tradisioneel verhoog glukagon bloedsuiker, maar matige aktivering van die glukagonreseptorverhoog energieverbruik (verhoog basale metaboliese tempo), bevorder lipolise (lipolise) en verbeter lewervetinhoud. Die potensiële glukemiese effek daarvan word geneutraliseer deur die kragtige GLP-1/GIP insulienotropiese effek, wat lei tot 'n netto effek van gewigsverlies terwyl glukemiese beheer gehandhaaf word.
Hierdie "driepuntige" ontwerp beteken dat die Retatrutide nie net van die innamekant af werk nie (verminder eetlus en eet), maar ook van die verbruikskant af (verhoogde energieverbruik en vetverbranding). Daar moet kennis geneem word dat die toevoeging van die glukagonbaan ook bykomende moniteringsvereistes vir hartklop, bloeddruk en glukosemetabolisme meebring.
Wat is die resultate van Fase II kliniese proewe?
Retatrutide van die mees besproke data kom van 'n fase II kliniese proef gepubliseer in die New England Journal of Medicine (NEJM) in 2023. Hierdie gerandomiseerde, dubbelblinde, placebo-beheerde studie het vetsugtige volwassenes ingeskryf en die gewigsverlies en veiligheid van verskillende dosisse Retatrutide oor 48 weke geëvalueer.
Die resultate toon duidelikdosisafhanklikgewigsvermindering effek. In die hoogste dosis (12 mg per week) groep het die gemiddelde gewig van proefpersone in week 48 vanaf die basislyn met ongeveer afgeneem 24%. This number is a rare high level in clinical studies of weight loss drugs, and the weight loss of some subjects is even close to the effect range of some weight loss surgery (bariatric surgery).
The following table summarizes the approximate weight loss performance of the key dose groups in the Phase II trial:
| average weight loss at 48 weeks | |
|---|---|
| placebo | approximately 2% |
| 4 mg | approximately 17% |
| 8 mg | approximately 23% |
| 12 mg | approximately 24% |
in addition to weight loss, the trial also observed improvements in metabolic parameters, including blood glucose, lipids and blood pressure parameters. In a parallel phase II study in patients with type 2 diabetes, Retatrutide also showed a significant reduction in glycated hemoglobin (HbA1c), suggesting its potential in blood glucose management.
It is worth taking a cautious view that the weight loss curve in the phase II trial has not yet shown a significant plateau at 48 weeks, which means that the final weight loss in the longer course of treatment is still unknown. At the same time, the phase II sample size is relatively limited, and key questions such as long-term safety, cardiovascular outcomes, and weight rebound after discontinuation need to be answered by larger phase III trials. Thus, these data, while encouraging, are still preliminary research evidence it should not be interpreted as an established clinical conclusion.
Phase III trial results (TRIUMPH items)
between December 2025 and November 2026, Lilly published the results of the first phase III trials in Retatrutide. All trials randomly assigned adults to either weekly Retatrutide or placebo, with diet and exercise and up-regulation from a lower starting level. Results are reported in two ways of analysis: therapeutic strategy (treatment-regimen) Estimated goals all randomizations were included, including those who stopped the drug; efficacy (efficacy) Estimated Target to estimate the effect of those who adhere to the treatment, the value is higher.
| Test | crowd | duration | mean weight change (highest treatment group vs. placebo) |
|---|---|---|---|
| TRIUMPH-4 (top line results, December 2025) | obese or overweight people with knee osteoarthritis without diabetes | 80 weeks | -28.7% vs. -2.1%(efficacy);-23.7% vs. -4.6%(treatment strategy) |
| TRIUMPH-1(NEJM,2026; 2339 adults) | obesity or overweight without diabetes | 80 weeks | -25.0% vs. -3.9%(treatment strategy);-28.3%(efficacy) |
| TRIUMPH-2(Lancet,2026; 1152 adults) | obese or overweight people with type 2 diabetes | 80 weeks | -18.8% vs. -5.1%(treatment strategy);-20.8%(efficacy) |
| TRIUMPH-3 (top-line results, July 2026; 1949 adults) | BMI 35 and above with confirmed cardiovascular disease | 80 weeks | -22.6% vs. -3.2%(efficacy) |
results other than weight: in TRIUMPH-4, the WOMAC scale-assessed knee pain dropped by up to 4.5 points, compared with a 2.4-point drop in the placebo group. TRIUMPH-1 also met the primary endpoint of knee osteoarthritis pain and apnea-hypopnea index in subjects with obstructive sleep apnea. In TRIUMPH-2, HbA1c fell 1.4 to 1.6 percentage points from 7.7 percent of baseline and 0.2 percentage points in the placebo group.
Security: the most common adverse events were gastrointestinal reactions (nausea, diarrhea, constipation, vomiting), which increased with treatment level. There were more reports of paresthesia (skin abnormalities or discomfort) than in the placebo group: up to 20.9 percent versus 0.7 percent in TRIUMPH-4 and about 6 percent versus 1 percent in TRIUMPH-3. The rate of discontinuation due to adverse events was 18.2 percent in the TRIUMPH-4 group, 13.5 percent in the TRIUMPH-3 group, and about 4 to 5 percent in the placebo group. TRIUMPH-3 was not a cardiovascular outcome trial and the number of major cardiovascular events was too small to be conclusive.
Follow-up progress: lilly said it plans to submit the Retatrutide's marketing application to the FDA in the first quarter of 2027. Lilly and the FDA are in litigation over whether Retatrutide should be reviewed under biologics, which will determine the type of application. Pending any regulatory approval, Retatrutide remains an investigational drug. Retatrutide not in within the scope of the US HHS Enforcement Discretion Policy issued on October 28, 2026 for six additional polypeptides (BPC-157, MOTS-c, Epitalon, Semax and KPV).
Postyd: 2026-11-13